PBYI
Puma Biotechnology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+44/100
Last price
9.50
▼ 0.17 (1.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.80
Prev close
9.67
Day high
9.80
Day low
9.43
Volume
322.65K
Market cap
$490.39M
P/E (TTM)
18.63
52W range
4.58 – 10.10
Day trading desk
Gap from prior close
+1.34%
Prior close 9.67
VWAP
9.53
-0.29% from price
Relative volume
1.27×
Normal
Session range
4.35%
9.43 – 9.84
Position in range
17%
Near session low
ATR (14D)
0.40
4.19% of price
Prior day high
9.78
PDH
Prior day low
9.33
PDL
Bid / ask spread
—
Quote not published
Session volume
410.88K
Avg 323.18K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.86%
-4.8%
1M
-0.52%
-1.7%
3M
+16.85%
+12.3%
6M
+36.30%
+18.1%
YTD
+59.66%
+45.4%
1Y
+85.19%
+68.8%
3Y
+261.22%
+179.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PBYI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+30.44K
Net buying
Buy transactions
8
239.00K shares
Sell transactions
10
208.56K shares
Net transactions
+18
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
7.89M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | CESANO ALESSANDRA Director |
SELL | 62.15K | $566.99K | Direct |
| Sep 14, 26 | CESANO ALESSANDRA Director |
CONVERSION | 50.00K | $146.50K | Direct |
| Sep 14, 26 | WILSON TROY EDWARD Director |
SELL | 5.00K | $45.50K | Direct |
| Jul 6, 26 | HUNT DOUGLAS M Officer |
SELL | 8.46K | $69.91K | Direct |
| Jul 6, 26 | NOUGUES MAXIMO F. Chief Financial Officer |
SELL | 9.39K | $77.56K | Direct |
| Jul 6, 26 | AUERBACH ALAN H Chief Executive Officer |
SELL | 44.06K | $364.05K | Direct |
| Jun 12, 26 | STUGLIK BRIAN M Director |
SELL | 8.10K | $58.31K | Direct |
| Jun 12, 26 | WILSON TROY EDWARD Director |
SELL | 10.80K | $77.75K | Direct |
| Jun 12, 26 | SENDEROWICZ ADRIAN M Director |
SELL | 27.00K | $194.31K | Direct |
| Jun 12, 26 | DORVAL ALLISON Director |
SELL | 11.61K | $83.58K | Direct |
| Jun 12, 26 | MOYES JAY M Director |
SELL | 22.00K | $158.80K | Direct |
| Jun 11, 26 | STUGLIK BRIAN M Director |
STOCK | 27.00K | $0 | Direct |
| Jun 11, 26 | CESANO ALESSANDRA Director |
STOCK | 27.00K | $0 | Direct |
| Jun 11, 26 | MILLER MICHAEL PATRICK Director |
STOCK | 27.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AUERBACH ALAN H |
Chief Executive Officer | 7.26M | Sale |
CESANO ALESSANDRA |
Director | 56.70K | Sale |
DORVAL ALLISON |
Director | 90.78K | Sale |
HUNT DOUGLAS M |
Officer | 196.84K | Sale |
LUDWIG JEFFREY JEROME |
Officer | 156.79K | Stock Award(Grant) |
MILLER MICHAEL PATRICK |
Director | 81.00K | Stock Award(Grant) |
MOYES JAY M |
Director | 58.32K | Sale |
NOUGUES MAXIMO F. |
Chief Financial Officer | 230.64K | Sale |
STUGLIK BRIAN M |
Director | 113.86K | Sale |
WILSON TROY EDWARD |
Director | 55.30K | Sale |
Fundamentals
Market cap$490.39M
Enterprise value$401.30M
Revenue (TTM)$231.24M
Gross profit$173.04M
EBITDA$40.12M
Net income$26.72M
EPS (TTM)$0.51
Free cash flow$32.47M
Total cash$93.90M
Total debt$4.82M
Book value / share$2.71
Shares outstanding51.62M
Float39.64M
Short % of float9.80%
Dividend yield0.00%
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E18.63
Forward P/E27.14
PEG ratio—
Price / sales—
Price / book3.50
EV / revenue1.74
EV / EBITDA10.00
Gross margin74.83%
Operating margin13.42%
Profit margin11.55%
Return on equity21.97%
Return on assets9.81%
Debt / equity3.48
Current ratio2.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $228.37M | $230.47M | $235.64M | $228.03M | -0.9% |
| Operating revenue | $228.37M | $230.47M | $235.64M | $228.03M | -0.9% |
| Cost of revenue | $58.16M | $64.40M | $62.68M | $55.09M | -9.7% |
| Gross profit | $170.21M | $166.06M | $172.96M | $172.94M | +2.5% |
| Research & development | $62.07M | $54.94M | $50.38M | $52.24M | +13.0% |
| Selling, general & admin | $71.21M | $80.68M | $89.93M | $89.98M | -11.7% |
| Total operating expense | $132.91M | $135.10M | $140.31M | $142.22M | -1.6% |
| Operating income | $37.30M | $30.97M | $32.64M | $30.72M | +20.5% |
| Net interest income | -$2.54M | -$7.73M | -$10.72M | -$10.78M | +67.1% |
| Pre-tax income | $35.78M | $24.10M | $22.67M | $457.00K | +48.5% |
| Tax provision | $4.67M | -$6.18M | $1.08M | $455.00K | +175.6% |
| Net income | $31.11M | $30.28M | $21.59M | $2.00K | +2.8% |
| Net income to common | $31.11M | $30.28M | $21.59M | $2.00K | +2.8% |
| Basic EPS | 0.62 | 0.62 | 0.46 | 0.00 | 0.0% |
| Diluted EPS | 0.61 | 0.62 | 0.45 | 0.00 | -1.6% |
| EBIT | $42.40M | $36.55M | $36.00M | $12.05M | +16.0% |
| EBITDA | $53.34M | $48.08M | $47.52M | $21.89M | +11.0% |
| Basic shares | 50.01M | 48.65M | 47.13M | 44.67M | +2.8% |
| Diluted shares | 50.65M | 49.10M | 47.55M | 44.93M | +3.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.64M | $69.22M | $84.58M | $76.20M | — | -57.2% |
| Cash & short-term investments | $97.53M | $100.97M | $95.94M | $81.07M | — | -3.4% |
| Accounts receivable | $53.65M | $32.01M | $47.84M | $40.35M | — | +67.6% |
| Inventory | $5.51M | $8.72M | $7.08M | $4.53M | — | -36.8% |
| Total current assets | $162.69M | $147.66M | $156.19M | $134.28M | — | +10.2% |
| Property, plant & equipment | $5.56M | $5.09M | $8.65M | $12.51M | — | +9.1% |
| Goodwill & intangibles | $41.39M | $51.13M | $60.87M | $70.61M | — | -19.0% |
| Total assets | $216.30M | $213.33M | $230.53M | $222.06M | — | +1.4% |
| Total current liabilities | $81.25M | $96.11M | $99.38M | $77.48M | — | -15.5% |
| Current debt | $22.52M | $45.33M | $34.00M | — | — | -50.3% |
| Long-term debt | — | $21.72M | $65.66M | $98.31M | $97.09M | — |
| Total debt | $28.55M | $74.08M | $111.49M | $114.28M | — | -61.5% |
| Total liabilities | $85.96M | $121.21M | $177.09M | $200.45M | — | -29.1% |
| Retained earnings | -$1.28B | -$1.31B | -$1.35B | -$1.37B | — | +2.4% |
| Shareholder equity | $130.34M | $92.13M | $53.44M | $21.61M | — | +41.5% |
| Working capital | $81.43M | $51.55M | $56.80M | $56.80M | — | +58.0% |
| Net tangible assets | $88.95M | $40.99M | -$7.43M | -$49.00M | — | +117.0% |
| Shares issued | 50.41M | 49.11M | 47.65M | 46.35M | — | +2.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $31.11M | $30.28M | $21.59M | $2.00K | +2.8% |
| Depreciation & amortisation | $10.94M | $11.52M | $11.52M | $9.84M | -5.1% |
| Stock-based compensation | $6.94M | $8.24M | $10.25M | $11.83M | -15.8% |
| Change in working capital | -$10.08M | -$3.54M | -$17.85M | -$44.50M | -185.1% |
| Operating cash flow | $41.80M | $38.92M | $27.01M | -$15.83M | +7.4% |
| Capital expenditure | -$71.00K | -$56.00K | -$12.64M | -$7.00M | -26.8% |
| Investing cash flow | -$36.19M | -$20.44M | -$19.13M | $7.10M | -77.1% |
| Financing cash flow | -$45.20M | -$33.85M | $0 | $12.22M | -33.5% |
| Free cash flow | $41.73M | $38.86M | $14.37M | -$22.83M | +7.4% |
| End cash position | $31.73M | $71.31M | $86.68M | $78.79M | -55.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $56.50M | $44.81M | $75.45M | $54.48M | $52.44M | +26.1% |
| Operating revenue | $56.50M | $44.81M | $75.45M | $54.48M | $52.44M | +26.1% |
| Cost of revenue | $12.47M | $10.42M | $23.13M | $12.17M | $12.30M | +19.7% |
| Gross profit | $44.03M | $34.39M | $52.33M | $42.30M | $40.13M | +28.0% |
| Research & development | $18.89M | $19.80M | $16.84M | $15.91M | $15.45M | -4.5% |
| Selling, general & admin | $17.55M | $18.42M | $18.38M | $17.03M | $18.41M | -4.8% |
| Total operating expense | $36.44M | $38.22M | $35.22M | $32.73M | $33.50M | -4.6% |
| Operating income | $7.58M | -$3.83M | $17.11M | $9.57M | $6.64M | +298.1% |
| Net interest income | $651.00K | $271.00K | -$142.00K | -$445.00K | -$881.00K | +140.2% |
| Pre-tax income | $8.24M | -$3.43M | $17.11M | $9.24M | $6.17M | +340.6% |
| Tax provision | $56.00K | $326.00K | $3.67M | $399.00K | $310.00K | -82.8% |
| Net income | $8.19M | -$3.75M | $13.44M | $8.84M | $5.86M | +318.2% |
| Net income to common | $8.19M | -$3.75M | $13.44M | $8.84M | $5.86M | +318.2% |
| Basic EPS | 0.16 | -0.07 | 0.27 | 0.18 | 0.12 | +328.6% |
| Diluted EPS | 0.16 | -0.07 | 0.26 | 0.17 | 0.12 | +328.6% |
| EBIT | $8.43M | -$2.70M | $18.23M | $10.73M | $8.00M | +412.5% |
| EBITDA | $10.94M | -$112.00K | $20.88M | $13.45M | $10.77M | +9,868.8% |
| Basic shares | 50.94M | 50.85M | 50.34M | 50.34M | 49.70M | +0.2% |
| Diluted shares | 52.60M | 50.85M | 51.52M | 50.93M | 50.14M | +3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36.54M | $36.19M | $29.64M | $53.52M | $54.66M | — | +1.0% |
| Cash & short-term investments | $93.90M | $101.55M | $97.53M | $94.39M | $96.02M | — | -7.5% |
| Accounts receivable | $34.06M | $26.33M | $53.65M | $33.56M | $25.91M | — | +29.4% |
| Inventory | $13.32M | $8.69M | $5.51M | $9.48M | $8.59M | — | +53.3% |
| Total current assets | $145.07M | $142.26M | $162.69M | $143.58M | $136.58M | — | +2.0% |
| Property, plant & equipment | $4.52M | $4.70M | $5.56M | $6.45M | $3.22M | — | -3.7% |
| Goodwill & intangibles | $36.52M | $38.96M | $41.39M | $43.83M | $46.26M | — | -6.3% |
| Total assets | $192.74M | $192.70M | $216.30M | $202.86M | $194.92M | — | +0.0% |
| Total current liabilities | $49.83M | $59.74M | $81.25M | $82.73M | $79.10M | — | -16.6% |
| Current debt | — | $11.28M | $22.52M | $33.72M | $34.00M | $45.33M | — |
| Long-term debt | — | — | — | — | $10.87M | $10.65M | — |
| Total debt | $4.82M | $15.95M | $28.55M | $41.05M | $49.23M | — | -69.8% |
| Total liabilities | $54.19M | $64.28M | $85.96M | $87.59M | $90.20M | — | -15.7% |
| Retained earnings | -$1.28B | -$1.29B | -$1.28B | -$1.30B | -$1.31B | — | +0.6% |
| Shareholder equity | $138.54M | $128.42M | $130.34M | $115.27M | $104.72M | — | +7.9% |
| Working capital | $95.25M | $82.52M | $81.43M | $60.85M | $57.48M | — | +15.4% |
| Net tangible assets | $102.02M | $89.46M | $88.95M | $71.44M | $58.46M | — | +14.0% |
| Shares issued | 51.10M | 50.88M | 50.41M | 50.38M | 49.62M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $8.19M | -$3.75M | $13.44M | $8.84M | $5.86M | — | +318.2% |
| Depreciation & amortisation | $2.52M | $2.58M | $2.66M | $2.72M | $2.76M | — | -2.6% |
| Stock-based compensation | $1.95M | $1.90M | $1.62M | $1.67M | $1.63M | — | +3.0% |
| Change in working capital | -$11.03M | $14.68M | -$6.54M | -$3.34M | $4.20M | — | -175.1% |
| Operating cash flow | $1.62M | $15.42M | $14.42M | $9.69M | $14.08M | — | -89.5% |
| Capital expenditure | — | — | — | -$26.00K | -$20.00K | -$61.00K | — |
| Investing cash flow | $7.97M | $2.47M | -$26.98M | $506.00K | -$11.25M | — | +222.2% |
| Financing cash flow | -$11.34M | -$11.33M | -$11.33M | -$11.33M | -$11.20M | — | -0.1% |
| Free cash flow | $1.62M | $15.42M | $14.46M | $9.66M | $14.06M | — | -89.5% |
| End cash position | $36.54M | $38.28M | $31.73M | $55.62M | $56.75M | — | -4.6% |
Options analytics
Put / call volume
0.22
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
7.50
-21.1% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+37.5%
Puts bid over calls
Call volume
37
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
7.50
0 contracts
Heaviest put OI
7.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.07 | 0.20 | +185.7% |
| Mar 2026 | -0.13 | -0.04 | +69.2% |
| Dec 2025 | 0.23 | 0.29 | +26.1% |
| Sep 2025 | 0.09 | 0.21 | +133.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell0 / 0
Held by insiders15.28%
Held by institutions75.63%
Institutions holding216
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.69
-1.98% from price
SMA 20
9.53
-0.30% from price
SMA 50
9.10
+4.42% from price
SMA 100
8.35
+13.80% from price
SMA 200
7.51
+26.48% from price
EMA 12
9.63
-1.38% from price
EMA 26
9.47
+0.27% from price
EMA 50
9.14
+3.94% from price
RSI (14)
50.8
Neutral
MACD (12,26,9)
0.16
Hist -0.04
ATR (14)
0.40
4.19% of price
Realised vol 30D
36.5%
Annualised
Bollinger upper
10.08
20, 2σ
Bollinger lower
8.98
20, 2σ
50 / 200 cross
Golden
9.10 vs 7.51
Trend bias
Above 200
+26.48%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.52
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
36.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-25.8%
Peak to trough
Max drawdown 5Y
-75.1%
Peak to trough
ATR 14
0.40
4.19% of price
Beta (reported)
1.21
5Y monthly, from filing
Short interest
Shares short
4.32M
Prior 4.17M
Change vs prior
+3.6%
Shorts adding
% of float
9.80%
Normal
% of shares out
8.37%
Against total outstanding
Days to cover
14.6
Crowded exit
Float
39.64M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| Feb 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 23, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 8, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 2, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-28
Proxy Statements
PRE 14A · 2026-04-07
Periodic Financial Reports
10-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2025-11-06
Periodic Financial Reports
10-Q · 2025-08-07
Headlines
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 1d ago
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Zacks · 19d ago
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Business Wire · 19d ago
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Business Wire · 27d ago
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Zacks · 28d ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 33d ago
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Zacks · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.